1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
14h
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...
STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...
TOKYO, Nov 5, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a ...
According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...
Since July 2020 Eisai's Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their ...
At CTAD 2024, Eisai will present the latest information on the use of lecanemab in clinical practice and the use of plasma biomarkers in the AHEAD 3-45 trial to screen for preclinical Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback